Building High-Value-Added FPCs and New Earnings Pillars
First written in FY2018. 8 of 16 entries say "Advanced", first in FY2019. Latest entry: 2026-10-26.
Taiyo Technolex moved to the "Worse" side of this theme in 2023.
1 other company's latest entry also says "Advanced".
- 2026-10-26AdvancedEarnings
「ディスプレイメーカー向けFPCの販売は減少したものの、医療機器メーカー、カメラメーカー及び産業機器メーカーをはじめとしたセットメーカー向け量産案件等の受注増により販売が増加したことから、売上高は増加いたしました。」
高付加価値FPCと新たな収益の柱について、販売先の構成変化を伴う量産案件の受注増が続いた。 - FY2026-H1AdvancedAnnual report
「Although sales of FPCs (Note 3) to display manufacturers declined, sales increased as a result of higher orders for mass-production projects and other products for set manufacturers (Note 4), including camera, medical equipment and industrial equipment manufacturers. Consequently, net sales increased to ¥1,323 million, up 14.1% year on year, and segment profit increased to ¥295 million, up 38.7%.」
Under the theme of high-value-added FPCs and new earnings pillars, sales to display manufacturers declined, but revenue and profit increased due to higher orders for mass-production projects and other projects for camera, medical-device and industrial-equipment manufacturers. - 2026-07-30AdvancedEarnings
「カメラメーカー、医療機器メーカー及び産業機器メーカーをはじめとしたセットメーカー向け量産案件等の受注増により販売が増加した」
ディスプレイメーカー向けFPC販売の減少がある一方、カメラ・医療機器・産業機器メーカー向け量産案件等の受注増が販売増として示された。 - FY2025Continued change in customer mixAnnual report
「Although sales of FPCs to medical equipment and display manufacturers declined, sales increased because mass-production and general prototyping projects for industrial equipment manufacturers and other set manufacturers increased.」
Sales to medical-device and display manufacturers declined, while mass-production and standard prototype projects for industrial equipment and other set manufacturers increased, resulting in continued polarization and changes in the customer mix. - FY2025-H1Polarization by customer categoryAnnual report
「Although sales of FPCs to medical-device and display manufacturers declined, sales of FPCs to set manufacturers, including camera manufacturers, increased, resulting in higher revenue. Profit increased due to lower labor costs and other expenses from voluntary employee departures, as well as the effect of a higher gross margin resulting from increased sales of in-house manufactured products. As a result, revenue was ¥1,159 million, up 0.5% year on year, and segment profit was ¥213 million, up 30.2%.」
Under the theme of high-value-added FPCs and new earnings pillars, sales to medical-device and display manufacturers declined while sales to set manufacturers, including camera manufacturers, increased, producing divergent results by customer category. The electronic circuit board business as a whole recorded 0.5% revenue growth and 30.2% profit growth. - FY2024AdvancedAnnual report
「We will increase orders for difficult, high-specification projects for medical devices and healthcare applications, as well as small- and medium-lot mass-production projects for industrial equipment. Although prototype projects accounted for more than 90% of orders when we specialized in prototype-related operations, mass-production projects have come to account for approximately 50% in recent years. An urgent priority is to establish a mass-production system while maintaining our prototype production capabilities.」
The theme of high-value-added FPCs and new earnings pillars was translated into specific initiatives involving difficult medical and healthcare projects and small- and medium-lot mass production for industrial equipment, demonstrating a structural shift in which mass-production projects expanded to approximately 50%. - FY2024-Q1WorsenedAnnual report
「Sales declined because FPC sales to other set manufacturers, display manufacturers and others decreased, mainly due to the prolonged inventory adjustments for consumer products and industrial equipment.」
While positioning high-value-added FPCs as a new earnings pillar, FPC sales to set manufacturers and display manufacturers declined because inventory adjustments for consumer products and industrial equipment were prolonged. - FY2023WorsenedAnnual report
「Sales declined because prolonged inventory adjustments for consumer products reduced sales to other set manufacturers, while fewer high-performance FPC projects reduced sales to medical equipment manufacturers.」
While pursuing high-value-added FPCs and the development of new earnings pillars, sales of high-function FPC projects and sales to medical-device manufacturers declined. - FY2023-Q3WorsenedAnnual report
「Sales declined because prolonged inventory adjustments reduced sales to other set manufacturers, while fewer high-performance FPC (Note 3) projects reduced sales to medical equipment manufacturers.」
The decline in high-performance FPC projects reduced sales to medical equipment manufacturers, while the impact of prolonged inventory adjustments also emerged among other set makers. The theme of making high-value-added FPCs a new revenue pillar weakened in the near term. - FY2023-Q2WorsenedAnnual report
「Although sales to medical equipment manufacturers declined because of fewer high-performance FPC (Note 3) projects and sales to other set manufacturers (Note 4) declined because of fewer in-house mass-production projects, sales to display manufacturers increased on solid demand for industrial touch panels and similar products, while sales to camera manufacturers increased as high-performance models were actively developed. As a result, net sales increased.」
The decline in high-value-added FPC projects for medical equipment and in-house mass-production projects emerged as lower sales, weakening some demand related to new revenue pillars. - FY2023-Q1WorsenedAnnual report
「Sales declined because demand for FPCs (Note 3) for medical equipment showed signs of leveling off, reducing high-performance product projects, while in-house mass-production projects for industrial equipment for set manufacturers (Note 4) also declined.」
The decline in projects involving highly sophisticated, high-value-added FPCs and in-house mass-production projects for industrial equipment weakened near-term demand related to developing new revenue pillars. - FY2022-Q3AdvancedAnnual report
「Although prototyping projects for FPCs for industrial equipment (Note 3) declined as the market showed signs of a pause, orders for in-house mass-production projects for industrial equipment, including industrial inkjet printers and drones, and for medical equipment remained strong, resulting in higher net sales. In terms of profit and loss, although higher orders for in-house mass-production projects increased the cost of sales, profit increased due to the impact of higher net sales. As a result, net sales were ¥1,966 million, up 9.6% year on year, and segment profit was ¥416 million, up 7.2%.」
Orders for in-house mass-production projects for inkjet printers, drones and medical equipment remained strong in connection with highly sophisticated, high-value-added FPCs and new revenue pillars, resulting in a 9.6% increase in revenue and a 7.2% increase in profit in the Electronic Substrates business. - FY2022-Q2AdvancedAnnual report
「Although prototyping projects for FPCs (Note 3) for digital cameras and industrial equipment declined as research and development activity paused, orders for in-house mass-production projects for industrial and medical equipment remained solid, partly because the rising cost of overseas production management increased the tendency to return production to Japan, resulting in higher net sales.」
With regard to high-value-added FPCs and new revenue pillars, orders for in-house mass-production projects for industrial and medical equipment remained strong, translating into higher sales. - FY2020AdvancedAnnual report
「The Company regards the medical equipment field, where the market is expected to grow further, as a priority area and will focus on strengthening its production structure with a view to covering the process from prototyping to mass production of highly sophisticated products and other products.」
Toward developing revenue pillars based on high-value-added, highly sophisticated products, the Company identified medical equipment as a priority area and specified the strengthening of its structure from prototyping through mass production. - FY2019AdvancedAnnual report
「The rebuilding of the head office plant, scheduled for completion in May 2021, has moved into full operation, and the Company will focus on enhancing and strengthening its production structure with a view to covering the process from prototyping to mass production of highly sophisticated products and other products expected to offer high profitability.」
Toward developing new revenue pillars, including highly sophisticated, high-value-added FPCs, the Company specified the rebuilding of the head office plant and the strengthening of its structure from prototyping through mass production. - FY2018First statedAnnual report
「From a long-term perspective, the FPC prototyping business is expected to gradually move toward high-value-added products, including highly sophisticated products. For the Group to continue growing, we believe it is necessary to further enhance the Group's recognition and credibility and develop businesses that can serve as new revenue pillars centered on the FPC business. We will seek further expansion by considering a broad range of options, including M&A focused on profitability, and allocating management resources efficiently.」
For the first time, the Company explicitly identified the transition to highly sophisticated, high-value-added FPCs and the development of new revenue pillars, including profitability-focused M&A, as growth strategies.